|1.||Ho, Peggy P: 3 articles (03/2010 - 11/2003)|
|2.||Steinman, Lawrence: 3 articles (03/2010 - 11/2003)|
|3.||Lee, Lowen Y: 2 articles (03/2010 - 11/2005)|
|4.||Fontoura, Paulo: 2 articles (11/2005 - 11/2003)|
|5.||Garren, Hideki: 2 articles (11/2005 - 11/2003)|
|6.||Utz, Paul J: 1 article (03/2010)|
|7.||Graham, Kareem L: 1 article (03/2010)|
|8.||Higgins, John P: 1 article (03/2010)|
|9.||Robinson, William H: 1 article (11/2005)|
|10.||Agrawal, Ashish: 1 article (11/2005)|
|1.||Autoimmune Diseases (Autoimmune Disease)
11/01/2005 - "These results demonstrate that suppressive GpG-ODN is a simple and highly effective novel therapeutic adjuvant that will boost the efficacy of Ag-specific tolerizing DNA vaccines used for treating Th1-mediated autoimmune diseases."
11/01/2003 - "In this study, we show that the application of an immunomodulatory GpG ODN, with a single base switch from CpG to GpG, can effectively inhibit the activation of Th1 T cells associated with autoimmune disease. "
11/01/2005 - "In conclusion, suppressive GpG-ODN effectively counteracted the undesired CpG-induced inflammatory effect of a tolerizing DNA vaccine in a Th1-mediated autoimmune disease by skewing both the autoaggressive T cell and B cell responses toward a protective Th2 phenotype. "
|2.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
11/01/2003 - "Moreover, this immunomodulatory GpG ODN suppresses the severity of experimental autoimmune encephalomyelitis in mice, a prototypic Th1-mediated animal disease model for multiple sclerosis."
11/01/2005 - "In chronic relapsing experimental autoimmune encephalomyelitis (EAE), combining a myelin cocktail plus IL-4-tolerizing DNA vaccine with a suppressive GpG oligodeoxynucleotide (GpG-ODN) induced a shift of the autoreactive T cell response toward a protective Th2 cytokine pattern. "
03/01/2010 - "Taken together, the data indicate that the protective mechanism of GpG-ODN treatment in the NZB/W model of lupus nephritis involves modulating T cell cytokine profiles and B lymphocyte activation through the inhibition of several TLRs, including TLR-7 and TLR-9."
03/01/2010 - "Treatment with a toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice."
|3.||Toll-Like Receptors (Toll-Like Receptor)
|4.||DNA (Deoxyribonucleic Acid)